U.S. gives Johnson & Johnson's COVID-19 vaccine a timeout

Out of an abundance of caution, the FDA and CDC have recommended a pause in the use of the only one-dose coronavirus vaccine available in the U.S. right now.

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The third coronavirus vaccine authorized for emergency use in the United States is going to sit in the corner by itself for a little while. On Tuesday morning, the Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement regarding Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine.

The agencies recommended that health care providers pause their use of Johnson & Johnson's vaccine until an advisory committee can review six cases in which inoculations were followed by dangerous blood clots. All six occurred in women between the ages of 18 and 48 years old. Most importantly, they were associated with a low concentration of blood platelets.

If there is an associated risk, it's an extremely small one. As of Monday, more than 6.8 million people had received Johnson & Johnson's COVID-19 vaccine.

At a rate of less than one patient in a million, this pause might seem like an excessive overabundance of caution. The agencies won't please anyone with this decision, but they really don't have another option.

Both AstraZeneca's (NASDAQ: AZN) COVID-19 vaccine and Johnson & Johnson's employ a non-replicating virus that delivers genetic instructions. The European Medicines Agency recently said unusual blood clots that present in combination with low platelet levels should be listed as a very rare side effect of AstraZeneca's COVID-19 vaccine after assessing dozens of cases similar to the six reported in association with J&J's vaccine.

Blood clots that break free and travel to the blood vessels that serve the heart and other organ systems can be fatal. Strong blood thinners are standard treatments for dangerous clots, but giving those to patients with low platelet concentrations can be just as dangerous. 

The Advisory Committee on Immunization Practices will meet on Wednesday, so based on its determination, injections with Johnson & Johnson's vaccine could be allowed to resume before the end of the week.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Delighted adult man, working on a company slogan, on his laptop.
International Stock News

Prediction: This artificial intelligence (AI) stock will be worth $5 trillion in 5 years

Amazon is integrating artificial intelligence (AI) across many areas of its business.

Read more »

Robot humanoid using artificial intelligence on a laptop.
International Stock News

Google must win at artificial intelligence or its search business could crumble. Does this make Alphabet an AI stock to buy?

Here's a deeper look into how Alphabet is faring in the battle for AI supremacy.

Read more »

A delivery man wearing a cap and smiling broadly delivers two boxes stacked on top of each other at the door of a female customer whose back can be seen at the edge of a doorway.
International Stock News

2 "Magnificent Seven" stocks billionaires are buying

The Magnificent Seven includes some of the most profitable and dominant tech companies in the world.

Read more »

Happy man working on his laptop.
International Stock News

Prediction: This artificial intelligence (AI) stock will be the biggest winner of 2025

Artificial intelligence will be one of the biggest growth opportunities this century.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
International Stock News

Could Warren Buffett's last move as Berkshire Hathaway CEO be buying this beaten-down "Magnificent Seven" stock?

Buffett is a value investor at his core, and he doesn't often buy shares of expensive companies.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Prediction: This artificial intelligence (AI) stock will be worth $5 trillion in 3 years

Let's take a closer look at the catalysts that could propel this stock toward that valuation.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

This Artificial Intelligence (AI) chipmaker just got a game-changing boost from Amazon, and Nvidia investors should be paying close attention

Amazon just made a notable investment in Nvidia's top rival.

Read more »

Happy man working on his laptop.
International Stock News

A once-in-a-decade opportunity: Here's why I'm buying Alphabet stock like there's no tomorrow

Alphabet's stock rarely gets this cheap, and right now could be a once-in-a-decade opportunity to scoop up shares at a…

Read more »